Skip to main content
Fig. 4 | Molecular Medicine

Fig. 4

From: Discovery of vanoxerine dihydrochloride as a CDK2/4/6 triple-inhibitor for the treatment of human hepatocellular carcinoma

Fig. 4

Effects of Vanoxerine dihydrochloride treatment on the expressions of proteins that play key roles in cell cycle progressions. a QHY7703 and b Huh7 cells were plated at 6-well plates with 0.125% FBS medium for 24 h and then with 10% FBS medium containing various concentrations (3, 10, 30 μM) of vanoxerine dihydrochloride. Cells were harvested after 6 h incubation and proteins analyzed by Western blotting. Western blotting results showed that vanoxerine dihydrochloride treatment significantly reduced the expressions of CDK2/4/6, Rb, pho-CDK2/4/6, pho-Rb and cyclin D/E in QGY7703 and Huh7 cells. As positive controls, three siRNAs targeting each of the CDK2/4/6 were designed as described previously (Shi et al. 2018), and used to inhibit the expressions of each of the CDK2/4/6proteins. *p < 0.05, significantly different from the control PBS treatment group

Back to article page
\